Navigation Links
PharmAthene Completes $6.5 Million Registered Direct Offering
Date:6/15/2011

ANNAPOLIS, Md., June 15, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has completed a previously announced registered direct offering raising gross proceeds for the Company of approximately $6.5 million.

Under the terms of the subscription agreements, PharmAthene sold an aggregate of 1,857,143 units to certain institutional investors for a purchase price of $3.50 per unit, with each unit consisting of one share of common stock and one warrant to purchase 0.2 of a share of common stock.  The warrants have a five year term and are immediately exercisable at an exercise price of $3.50 per share.

The net proceeds to the Company are approximately $5.8 million after placement agent fees and other offering expenses.  PharmAthene intends to use the net proceeds from the offering for general corporate purposes.

Leerink Swann served as lead placement agent and Noble Financial Capital Markets served as co-placement agent in the offering.  The securities described above were offered by PharmAthene pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission.  Additional information and details with respect to the offering are included in a prospectus supplement that PharmAthene has filed with the Securities and Exchange Commission. The registration statement and prospectus supplement may be obtained from the Securities and Exchange Commission's website at www.sec.gov. This press release does not constitute an offer to sell, nor is it a solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. The securities may
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Reports First Quarter 2011 Financial and Operating Results
2. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
3. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
4. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
5. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
6. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
7. PharmAthene Announces Pricing of $15 Million Public Offering
8. PharmAthene Announces Proposed Common Stock Offering
9. PharmAthene Announces $3.9 Million Registered Direct Offering
10. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
11. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... SOUTH SAN FRANCISCO, Calif., Aug. 27 Poniard,Pharmaceuticals, ... focused,on oncology, today announced that Jerry McMahon, Ph.D., ... in early September: The Thomas Weisel Partners ... p.m. Eastern time at the Four Seasons Hotel ...
... Aug. 27 Sanofi-aventis,U.S. launched today a new ... (oxaliplatin injection) for patients who have,adjuvant stage III ... to offer more convenience, efficiency and safety in ... had been,available in 50 mg and 100 mg ...
... Diabetes Meta-Database to Quantify Competitive Treatment Landscape and Accelerate ... ... MOUNTAIN VIEW, Calif., Aug. 27 Pharsight,Corporation (OTC Bulletin Board: ... clinical drug development, today,announced that it has licensed its public-source ...
Cached Biology Technology:Poniard Pharmaceuticals Announces Participation in Upcoming Conferences 2New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 2New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 3New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 4New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 5New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 6New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 7Pharsight Achieves First License Sale for Public-Source Database 2Pharsight Achieves First License Sale for Public-Source Database 3
(Date:7/10/2014)... teens living with a cardiac pacemaker, a low sense ... life, reports a study in the July ... official journal of the Society for Developmental and ... Lippincott Williams & Wilkins , a part of ... as a protective factor against lower health-related quality of ...
(Date:7/10/2014)... used to control everyday household items such as washing ... for conservation, a new study has claimed., As part ... scientists and mathematicians, including those from the University of ... engineering, could be replicated in the natural world to ... ,integral control, - in essence a built-in feedback control ...
(Date:7/10/2014)... Consuming a whole fresh avocado with either an orange-colored ... carotenoid (alpha- and beta-carotene) absorption and conversion of these ... to new research (1) published in The ... A is involved in reproductive health and growth promotion; ... has antioxidant properties. Provitamin A carotenoids, like alpha- and ...
Breaking Biology News(10 mins):For children with pacemakers, 'self-competence' affects quality of life 2Feedback control could be key to robust conservation management 2New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2
... Kolls, Professor and Chairman of Genetics at the LSU Health ... a $2.1 million grant over five years by the National ... Health to further his work on a discovery that plays ... Bacterial pneumonia is an important clinical problem and defense mechanisms ...
... a first-of-its-kind cloth that releases nitric oxide gas an ... a wrap to help preserve organs harvested for transplantation. The ... bi-weekly journal. Kenneth Balkus and Harvey Liu note in ... flow and regulates a range of other body functions. Scientists ...
... drugs are embracing new tactics to deal with an ... far from being won. That,s the focus of an ... Engineering News (C&EN) , ACS, weekly newsmagazine. Counterfeiting ploys ... to identify their products as genuine. C&EN Associate ...
Cached Biology News:LSUHSC awarded multi-million dollar grant to reduce pneumonia 2
... ESGRO Complete Derivation Kit is ... ES cells from delayed blastocysts in ... Clonal ... Delayed Blastocyst Incubation Medium Trypsin ...
Template and primers for preparation of internal control spots...
Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
ANTI K. AEROGENES...
Biology Products: